# Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

> **NCT01997190** · PHASE1 · COMPLETED · sponsor: **Candel Therapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Malignant Pleural Effusion
- Lung Cancer
- Mesothelioma
- Breast Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** AdV-tk + valacyclovir

## Key facts

- **NCT ID:** NCT01997190
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-12
- **Final completion:** 2018-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997190, "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01997190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*